Proton-pump inhibitor use and the risk for community-acquired pneumonia

被引:210
作者
Sarkar, Monika [1 ]
Hennessy, Sean [1 ]
Yang, Yu-Xiao [1 ]
机构
[1] Univ Penn, Ctr Clin Epidemiol & Biostat, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.7326/0003-4819-149-6-200809160-00005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent studies suggest that proton-pump inhibitors (PPIs) may increase the risk for community-acquired pneumonia (CAP). Objective: To examine the association between PPI use and CAP in adults followed in general practices in the United Kingdom. Design: Nested case-control study. Setting: The General Practice Research Database (1987 to 2002) in the United Kingdom. Participants: Patients age 18 years or older with at least 6 months of initial pneumonia-free follow-up in the database. Case patients (n = 80 066) were defined as those who received an incident diagnosis of CAP. Control participants (n = 799 881) were selected by using incidence density sampling, matching on practice site, calendar period, and follow-up duration. Measurements: Use of PPIs within 30 days before the index date. Adjusted odds ratios (ORs) were estimated by using conditional logistic regression, adjusting for potential confounders. Results: Overall, current PPI use was not associated with an increased risk for CAP (adjusted OR, 1.02 [95% CI, 0.97 to 1.08]) or risk for CAP that required hospitalization (adjusted OR, 1.01 [CI, 0.91 to 1.12]). There was a strong increase in risk for CAP associated with current use of PPI therapy that was started within the previous 2 days (adjusted OR, 6.53 [CI, 3.95 to 10.80]), 7 days (adjusted OR, 3.79 [CI, 2.66 to 5.42]), and 14 days (adjusted OR, 3.21 [CI, 2.46 to 4.18]), but there was no statistically significant association for longer-term current PPI therapy. A separate matched case-control analysis, which included the 3 strongest confounders as additional matching factors, yielded similar results as the primary analysis (adjusted OR, 0.96 [CI, 0.91 to 1.02]). Limitations: Adherence to PPI prescription was assumed to be 100%. No radiographic evidence was available to corroborate a diagnosis of CAP. Conclusion: Proton-pump inhibitor therapy started within the past 30 days was associated with an increased risk for CAP, whereas longer-term current use was not.
引用
收藏
页码:391 / W75
页数:10
相关论文
共 27 条
[1]  
[Anonymous], 1994, Pharmacoepidemiology) and Drug Safety
[2]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[3]   THE READ CLINICAL CLASSIFICATION [J].
CHISHOLM, J .
BRITISH MEDICAL JOURNAL, 1990, 300 (6732) :1092-1092
[4]  
de Abajo F J, 2001, BMC Clin Pharmacol, V1, P1, DOI 10.1186/1472-6904-1-1
[5]   Use of proton pump inhibitors and the risk of community-acquired pneumonia - A population-based case-control study [J].
Gulmez, Sinem Ezgi ;
Holm, Anette ;
Frederiksen, Henrik ;
Jensen, Thoger Gorm ;
Pedersen, Court ;
Hallas, Jesper .
ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (09) :950-955
[6]   Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole [J].
Hartmann, M ;
Theiss, U ;
Huber, R ;
Luhmann, R ;
Bliesath, H ;
Wurst, W ;
Lucker, PW .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (03) :359-366
[7]  
Hollowell J, 1997, Popul Trends, P36
[8]   PROBLEM OF PROTOPATHIC BIAS IN CASE-CONTROL STUDIES [J].
HORWITZ, RI ;
FEINSTEIN, AR .
AMERICAN JOURNAL OF MEDICINE, 1980, 68 (02) :255-258
[9]  
Ip S, 2005, COMP EFFECTIVENESS R, V1
[10]   Chronic cough due to gastroesophageal reflux disease - ACCP evidence-based clinical practice guidelines [J].
Irwin, RS .
CHEST, 2006, 129 (01) :80S-94S